Lenalidomide has been shown to: (i) directly down-regulate PD-L1 expression on MM PCs, (ii) decrease the levels of regulatory T cells (Tregs), (iii) co-stimulate T and NK cells and (iv) down-regulate PD-1 expression on T cells (34, 38, 46–48). Here, CD274 is linked to Miyoshi myopathy.